1. Aarkstore.com announces, The Latest market research report is available in
its vast collection:
Pancreatic Cancer – Pipeline Review, H1 2012
You can also request for sample page of above mention reports on
sample@aarkstore.com
Summary
Global Markets Direct’s, Pancreatic Cancer - Pipeline Review, H1 2012, provides an
overview of the Pancreatic Cancer therapeutic pipeline. This report provides
information on the therapeutic development for Pancreatic Cancer, complete with
latest updates, and special features on late-stage and discontinued projects. It also
reviews key players involved in the therapeutic development for Pancreatic Cancer.
Pancreatic Cancer - Pipeline Review, H1 2012 is built using data and information
sourced from Global Markets Direct’s proprietary databases, Company/University
websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by
Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Pancreatic Cancer.
- A review of the Pancreatic Cancer products under development by companies and
universities/research institutes based on information derived from company and
industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
2. - A feature on pipeline projects on the basis of monotherapy and combined
therapeutics.
Table of contents:
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metastatic Hormone Refractory Prostate Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Metastatic Hormone Refractory Prostate
Cancer 8
Metastatic Hormone Refractory Prostate Cancer Therapeutics under Development
by Companies 10
Metastatic Hormone Refractory Prostate Cancer Therapeutics under Investigation
by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Products under
Development by Companies 16
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Products under
Investigation by Universities/Institutes 17
Companies Involved in Metastatic Hormone Refractory Prostate Cancer
Therapeutics Development 18
Genentech, Inc. 18
Oxford BioMedica plc 19
Millennium Pharmaceuticals, Inc. 20
Metastatic Hormone Refractory Prostate Cancer – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
3. Assessment by Molecule Type 25
Drug Profiles 27
TAK-700 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
AZD2171 + Docetaxel + Prednisone - Drug Profile 29
Product Description 29
Mechanism of Action 29
List of Figures
List of Tables are also include.
For more related Reports Plz follow The link:
Pipeline Review, H1 2012
http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H1
2012&PubId=&pagenum=1
Erosive Oral Lichen Planus – Pipeline Review, H1 2012
Pancreatic Cancer – Pipeline Review, H1 2012
Metastatic Hormone Refractory Prostate Cancer – Pipeline Review, H1 2012
Myasthenia Gravis – Pipeline Review, H1 2012
Dental Plaque – Pipeline Review, H1 2012
4. Esophagitis – Pipeline Review, H1 2012
Retinitis Pigmentosa (Retinitis) – Pipeline Review, H1 2012
Cellulite – Pipeline Review, H1 2012
HIV Pain – Pipeline Review, H1 2012
Tropical Spastic Paraparesis – Pipeline Review, H1 2012
Search More Reports Related to This Category :
Pharmaceuticals and Healthcare
http://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals and
Healthcare&PubId=&pagenum=1
For More details Plz do contact :
Aarkstore Enterprise
Lavanya
Phone:08149852585
Email: enquiry@aarkstore.com